FIGHT-207

FIGHT-207 is a multi-centre international study to evaluate the efficacy and safety of pemigatinib in participants with activating FGFR mutations or translocations.

Full title: Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

This study is currently open at two centres in the UK:

  • Sarah Cannon Institute, London – Dr Tobias Arkenau
  • University College Hospital, London – Professor John Bridgewater

More details of the study can be found here:
https://clinicaltrials.gov/ct2/show/NCT03822117

Also, see:
https://bepartofresearch.nihr.ac.uk/ and search for Study: FIGHT-207

Incyte:  https://www.incyte.com

Back to previous page